Available Induction Regimen Options for Patients with Transplant-Eligible NDMM

Video

The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
4 experts in this video
4 experts in this video
Related Content